Embedded Files
There are no skincare products on the market to prevent the progression of pressure ulcers, leaving more than 15 million patients in the US alone at risk.
There are no skincare products on the market to prevent the progression of pressure ulcers, leaving more than 15 million patients in the US alone at risk.
Pressure ulcers, also known as bed sores, are skin ulcers that result from prolonged pressure at points of contact of the body with other surfaces. They are most common in elderly individuals and patients with significantly limited mobility.
How Serinex is reducing the risk of pressure ulcers with DuraDerma
How Serinex is reducing the risk of pressure ulcers with DuraDerma
Addressing an unmet medical need
Addressing an unmet medical need
No labeled products have demonstrated prevention in large, randomized, multi-center trials specifically for ulcers.
A topical cream made with silk
A topical cream made with silk
When used alongside standard care, DuraDerma strengthens the skin, enhancing resilience against mechanical breakdown.
Adding integrity to vulnerable skin
Adding integrity to vulnerable skin
Preclinical studies have compared DuraDerma to non-specific gels and demonstrated superior prevention.
Who is at risk of pressure ulcers?
Who is at risk of pressure ulcers?
Elderly
Post-surgical recovery
Newborns
2.5 million pressure ulcers
2.5 million pressure ulcers
$16 billion in cost of care
$16 billion in cost of care
22+ million pressure ulcers
22+ million pressure ulcers
12.8% incidence in global hospitalized adults
12.8% incidence in global hospitalized adults
Partner with Serinex Medical
Partner with Serinex Medical
Serinex Medical is entering an exciting phase of growth as we advance our platform toward commercialization. To support this next phase, we are currently engaging with partners and investors who share our commitment to transforming care for patients suffering from pressure ulcers.
Serinex Medical is entering an exciting phase of growth as we advance our platform toward commercialization. To support this next phase, we are currently engaging with partners and investors who share our commitment to transforming care for patients suffering from pressure ulcers.
We welcome collaboration and dialogue with those interested in supporting our mission - whether through investment, strategic partnership, or scientific engagement. To learn more or get involved, please reach out to our team.
We welcome collaboration and dialogue with those interested in supporting our mission - whether through investment, strategic partnership, or scientific engagement. To learn more or get involved, please reach out to our team.
Together, we can accelerate innovation and bring meaningful therapies to those who need them most.
Together, we can accelerate innovation and bring meaningful therapies to those who need them most.
Page updated
Report abuse